A positive correlation between serum levels of mature brain-derived neurotrophic factor and negative symptoms in schizophrenia

作者：Niitsu Tomihisa^*; Ishima Tamaki; Yoshida Taisuke; Hashimoto Tasuku; Matsuzawa Daisuke; Shirayama Yukihiko; Nakazato Michiko; Shimizu Eiji; Hashimoto Kenji; Iyo Masaomi

来源：Psychiatry Research, 2014, 215(2): 268-273.

DOI：10.1016/j.psychres.2013.12.009

• Mature BDNF
• MMP-9
• Biomarker
• ELISA
• Smoking
• Gender
• SANS

A meta-analysis study reported serum brain-derived neurotrophic factor (BDNF) levels as a potential biomarker for schizophrenia. However, at the time, commercially available human ELISA kits were unable to distinguish between pro-BDNF (precursor BDNF) and mature BDNF, because of limited antibody specificity. Here, we used new ELISA kits, to examine serum levels of mature BDNF and matrix metalloproteinase-9 (MMP-9), which converts pro-BDNF to mature BDNF in schizophrenia. Sixty-three patients with chronic schizophrenia and 52 age- and sex-matched healthy controls were enrolled. Patients were evaluated using the Brief Psychiatry Rating Scale, the Scale for the Assessment of Negative Symptoms (SANS) and neuropsychological tests. Neither serum mature BDNF nor MMP-9 levels differed between patients and controls. In male subgroups, serum MMP-9 levels of smoking patients were higher than those of non-smoking patients, but this was not observed in male controls or the female subgroup. In patients, serum mature BDNF levels were associated with SANS total scores and the Information subtest scores of the Wechsler Adult Intelligence Scale Revised (WAIS-R), while serum MMP-9 levels were associated with smoking and category fluency scores. These findings suggest that neither mature BDNF nor MMP-9 is a suitable biomarker for schizophrenia, although further studies using large samples are needed.

• 出版日期2014-2-28